article thumbnail

Understanding the care for older people in rural China: The role of primary care providers as "the third sphere" [Global health]

Annals of Family Medicine

To address this crisis, China has launched the National Essential Public Health Services (NEPHS) program in 2009, which includes several elderly care initiatives. We advise the government to engage "quasi-officials" in the "third sphere" with the primary care policy-making process in the future. However, its future remains uncertain.

article thumbnail

Oregon-based medical group Northwest Permanente announces affiliation with The Permanente Medical Group of Northern California

Permanente Medicine

Kaiser Permanente in Northern California received 4.5 We are dedicated to the mission of improving the health of our patients and communities.

Medical 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Biogen agrees to pay $900 million in largest FCA Settlement Ever Secured without Government’s Intervention

FDA Law Blog

Mr. Bawduniak alleged that, between 2009 and 2014, Biogen paid illegal kickbacks to its largest prescribers to induce them to prescribe the company’s multiple sclerosis drugs, Avonex, Tysabri and Tecfidera, and discourage them from prescribing newer competitor products. This lawsuit was brought to the U.S. See United States ex rel.

article thumbnail

15 Years Strong: Rare Disease Week’s Remarkable Journey of Support

FDA Law Blog

Sasinowski — In 2009 — 15 years ago — the National Organization for Rare Disorders (NORD) announced the first U.S. In 2009 I served as Chair of NORD and through the hard work of countless colleagues we inaugurated the first Rare Disease Day. By Frank J. recognition of Rare Disease Day.

article thumbnail

From GRP to SIUU – the Evolution of FDA Guidance on Off-Label Dissemination of Scientific Information

FDA Law Blog

Previous iterations of this guidance from 2009 and 2014 (blogged on here and here ) were known as Good Reprint Practices (GRP). While the information in the SIUU Guidance is a welcome departure from FDA’s more restrictive approaches under GRP, it may not go far enough.

Clinic 64
article thumbnail

The Most Engaging Decision You’ll Read All Year – Five Stars

FDA Law Blog

Koblitz — You know a court decision is going to be worth reading when the judges compare FDA’s regulatory governance of flavored e-cigarettes to a Shakespearean gaslighting. By David B. Clissold & Sara W.

article thumbnail

Separating the Hype from the Hyperbole Surrounding FDORA’s Alternatives to Animal Testing under the FD&C Act

FDA Law Blog

While these changes to the IND and the biosimilarity provisions represent real changes to the words governing FDA’s authority under the FD&C Act, we think it is worth asking just how measurable and immediate an impact they will have on day-to-day decision-making of the FDA and its review staff. FDORA § 3209(b).

Clinic 64